Growing inventories of cord blood units have facilitated access to umbilical cord cell transplantation for many patients lacking conventional stem cell donors. They are in principle 'off-the-shelf', 'fit-for-use', as well as safe and effective therapy products. Cellular enumeration is used as a surrogate of graft potency, and users rely on the rigorous assessment carried out in banks to avoid poor engraftment after thawing (loss of cells or poor function), when the patient's situation is critical. However, in practice, when units are selected, initially on the basis of HLA matching and cell dose assessment, their absolute quality remains uncertain. Unfortunately, quality-related issues (particularly related to viability) are not uncommon in cord blood transplantation. The reasons for potency failures are diverse, but a lack of thorough validation during critical steps of the process and of appropriate use of quality-control tools for timely detection of problematic units are significant contributors. Moreover, incongruence between different sets of standards and regulations, and lack of common quality systems between banks result in a highly heterogeneous international inventory. Therefore, this complicates the matter for the end user of the product. To ameliorate this situation, it is essential to improve quality at each of the critical manufacturing steps wherein potency can be threatened, thereby creating homogeneous inventories of units with excellent quality and quantity.
Introduction
Cord blood contains naturally mobilized progenitor cells that have the capacity to engraft and reconstitute the haematopoietic system of an individual. 1 This ability was shown when Gluckman et al. 2 performed the first cord blood transplantation (CBT), with subsequent confirmation over the past 20 years, with 20 000 procedures having been conducted. 3 In spite of the low blood volume left in the placenta and collected in the cord blood unit (CBU), in approximately half of the collections, a single unit may reconstitute the full haematopoietic system of an adult patient. [4] [5] [6] A combination of large-scale banking and transplantation development has made cord blood an alternative source for BMT. 7 Cord blood has a number of advantages compared with other stem cell sources. In terms of safety, although a waste product, adequately collected, it is not harmful to the donor and has a low risk of transmission of communicable diseases. [8] [9] [10] The ability to conduct HLA-incompatible transplants allows for the efficient and affordable design of national inventories improving access to stem cell therapy for almost all patients in need. 11 In terms of logistics, it develops the concept of 'off-the-shelf' therapy, providing near-immediate access for all patients who require an SCT. 12 Furthermore, it also opens new avenues for developing alternative transplantation therapies and novel non-haematopoietic applications. 13, 14 During the past 20 years, outcomes of CBT progressively improved. [15] [16] [17] [18] This was attributed to a combination of better clinical management and patient selection, development of standardized and novel clinical protocols and conditioning regimens, and overwhelmingly, especially in the adult setting, the increase in the number and quality of units offered, thus allowing transplantation of more cellular products with better match.
Pitfalls in cord blood banking
Despite this experience, many problems remain to be resolved to improve outcomes further. It is not unusual that the cell-processing laboratory at the transplant centre reports issues on receipt of the product and following thawing. Examples of serious events typically communicated are poor cell viability and yield (that is, far below 50%, or failure in colony-forming unit (CFU) growth after thawing); 19, 20 mislabelling; 21 or accidents during transport, including receipt of thawed units, broken bags or improperly labelled products. 22, 23 Cord blood is easily collected and manufactured but not without risk. Compared with typical adult sources, it includes a cryopreservation step in samples that have usually aged 424 h. Processing automation facilitated banking growth but undermined the capacity to perform exhaustive in-process quality control. In addition, general knowledge on quality assessment has not spread at the same speed. Warning reports have been published describing severe losses of viable stem cells after thawing. 24, 25 Worryingly, many CBUs were stored without an attached segment, making it impossible to confirm the cellular content and viability later on. As we mentioned, the fast development of worldwide inventories with limited validation (that is, banks without transplantation data on engraftment and follow-up), the lack of 'fit-for-purpose' integrated quality management systems and the delayed acquisition of common international standards (first set developed in 2000, 26 but at present, only 19 have been granted Foundation for Accreditation on Cell Therapy (FACT)-Netcord accreditation worldwide) has contributed to an ambience of distrust between the banks and end users. After growing to a reasonable size, the banks need to now focus on improving quality. In spite of the 400 000 Units available worldwide, it is clear that many of these units need to be assessed and judged 'fit for purpose' on the basis of current recommended practice, thereby defining the actual number of reliable quality units. Figure 1 simulates a distribution of the current worldwide inventory stressing the qualitative problems discussed above, and suggesting that a small percentage of them are really acceptable products.
Promotion of congruent international standards is relevant because as shown in the last update of WMDA (World Marrow Donor Association), 27 42% of the cord blood activity resulted from imported units. Communication and harmonization between the Netcord Foundation, FACT, WMDA and other stakeholders with public health representatives to gain consensus on releasing test criteria and searching policies is required, with the intention of achieving an international harmonization on accreditation and policy. A FACT-Netcord joint venture pioneered this initiative and became the first true international body to conduct the same strategy of inspection worldwide for all cord blood bank modalities. 28 This process validates the quality management system in these centres, affirming the storage of reliable units and should constitute an important requirement in the future to regain confidence in the international CBUs available for public use.
Quality as a tool to improve outcomes
Every pharmaceutical product has to establish identity, strength, purity and other quality characteristics designed to ensure the required levels of safety and effectiveness. Cord blood banks, as tissue therapy centres, must ensure Figure 1 Figurative representation of the quality of the international cord blood inventory (400 000 Units from 107 cord blood banks according to www.bmdw.org) and suitability for adult and paediatric transplantation on the basis of accreditation, administrative and quantitative factors-The Iceberg effect.
The cord blood bank dilemma S Querol et al that the product is disease free, and that its manufacturing process prevents contamination and preserves integrity and function. Existing and new cord blood bank establishments need to design and develop quality management systems that ensure that the product consistently attains its predefined quality at the end of the process. 29, 30 Below, our review will concentrate on determining which are the critical steps of the cord blood process, especially those that can affect final cell viability, and will discuss which releasing tests need to be conducted to reassure that the unit selected is 'fit for purpose'.
Building quality: validation Discussion on traceability and safety can be found elsewhere. 20, 21 However, there are no reports ascertaining how many engraftment failures are due to low graft viability. In Figure 2 , we show the results of the first CBUs used at the King's College Hospital cord blood programme, and it is clear that there is marked variability in cell recovery and viability observed. In our experience, up to 9 out of 17 thawed units (53%) had problems in cell enumeration. These accounted for cell yields o50% in many cases, and exceptionally big discrepancies in CD34 enumeration, perhaps reflecting the difficulties in the standardization of these particular tests when using thawed samples.
Other authors have reported the same issues regarding graft potency, 19 and remarkably Barker et al. presented data suggesting that in double CBT, the unit that preferentially engrafts is that having better viability. 31 Worryingly, 430% of the units used for transplantation in their series had CD34 viability o75%.
In principle, transplant data suggest that the graft content of CD34 þ progenitors, and especially, that of CFUs correlates with the speed of engraftment and longterm survival. [32] [33] [34] [35] [36] These data suggest that a simple assessment of viable CD34 can be used as a surrogate of cord blood potency. At the moment, the best practice is to follow the international ISHAGE (International Society of Hematotherapy and Graft Engineering) recommendations to enumerate CD34 þ events and using 7-Actinomycin D as a viability marker, 37 but maintaining CFU assay to assess the stem cell function. New methods, especially the so-called 'functional flow cytometry' that assess early apoptosis are required to increase sensitivity and reduce the time it takes to obtain culture results. 24 We are validating a method using the early apoptosis marker, Annexin-V, and the ISHAGE gating strategy 38 to improve the functional assessment of cord blood grafts. From these data, we observed that a substantial number of CD34 þ events were 7-Actinomycin D negative but stained for Annexin-V (25% more on average), indicating further functional impairment. In our hands, this approach better predicts CFU than 7-Actinomycin D alone, especially in thawed samples, and might become an ideal releasing test.
Procurement. Cells are obtained after cord clamping. Collection techniques may influence the volume harvested but should not influence cell viability. In contrast, conditions during delivery influence the number of progenitors and cells in the graft, especially high in stressful labours.
39,40 Figure 3 shows the distribution of CD34 þ cells per microlitre of cord blood collected. The majority of products range from 20 to 100 with some significant outliers above these figures. Interestingly, as transplant centres request high cell dose, these outliers are the grafts preferentiality selected for transplantation.
Cells are drained into a conventional blood donation bag with anticoagulant (citrate-phosphate-dextrose in most of the cases) adjusted to 25-35 ml. This introduces variability as units collected with little volume might have excess anticoagulant that might interfere with cellular performance. Another theoretical issue is that the plastic composite of the collection bag was originally designed to contain red cells and may prove suboptimal for cord blood storage akin to what happened with platelet function. 41 These aspects have never been analysed in the context of cord blood banking, and only indirect evidence suggests that this type of collection bag is not critical, at least if the process is conducted in the first 24 h after collection. Longer contact times are still a matter of scientific debate, in spite of the standards allowing processing up to 72 h after collection in private banking. The cord blood bank dilemma S Querol et al
After collection, there is a preference to use cool environments for transit times longer than 24 h. [42] [43] [44] It is very important that each bank generates its own validation on the basis of CD34 þ viability or CFU assessment before selecting time and temperature parameters for non-frozen storage and transport. Furthermore, these studies should also analyse the product after thawing as the viability problem might be magnified after cryopreservation. 45 Transport containers need to minimize temperature changes and include temperature logs to register temperature variations. As a reference, Table 1 shows the data on the procurement validation at the Anthony Nolan Cord Blood Bank.
Processing. At reception, many cord blood banks have threshold policies, which remove units that are 448 h old from the collection and units below a defined volume or cell content. According to the US Food and Drug Administration recommendations, 46 values that help to make this decision are suggested in Table 2 . Conservation in the processing laboratory is sometimes poorly defined. There are two periods wherein units can be at risk: one, immediately after reception and before volume reduction (if this occurs), and second, after volume reduction and before starting cryoprotectant addition. In particular, this second period can be critical if the bank uses colloids to improve yield after red cell depletion (that is, starch) as the cells conserved in these solutions sediment, generating a high concentrated pellet if the bag is kept statically on the bench or in the fridge.
Another potential interference in potency is the technique used for volume reduction and the protocol used for that. Time and temperature of this process, as well as speed of centrifugation can be detrimental to final viability, and again this needs to be carefully tested in each cord blood bank programme. In general, standards only recommend plasma and red cell depletion to reduce the cord blood volume. It is helpful to establish a minimum total nucleated cell yield for quality control (that is, we use 50% as reference). To minimize variability on yield, automation is beneficial, especially in cord blood banks with a high turn over. Different systems are commercially available, including Sepax, AXP and others. 47 These systems have the ability to register critical parameters during the process, including volume, spinning speed and time.
Finally, another parameter that can affect viability is the final haematocrit, and this should be reported to the transplant centre. 48 Cryopreservation and long-term storage. It is important to ensure that the processing of each single unit is performed by a single technician to minimize the risk of mislabelling. Cells can be potentially damaged depending on time and temperature during the cryoprotectant addition. 47 We use the Coolmix Device (Biosafe, Eysins, Switzerland) that registers temperature at the time of DMSO mixing, increasing the repeatability of the process. After freezing, units need to be sealed and packed within the canisters. This is a risky manoeuvre again but does not directly affect potency, unless warming occurs due to excessive handling. Other major risks of this step include tube sealing that can put the bag integrity at risk. Particular attention needs to be paid to the type of bags used, the canister adaptability and the overwraps added to prevent cross-contamination in case of bag damage. Cryovials should be avoided as sample handling, especially thawing, is complex and may generate unexpected variables.
After freezing, the unit needs to be placed in the quarantine space before finally being transferred to the long-term storage tank. Any event that results in an increase of temperature above À130 1C is considered a significant warming event. Their accumulation during the storage can theoretically affect cell viability after thawing due to unstable glass transition. This individual thermal history of the sample adds additional certainty that the integrity and viability of the samples is maintained. It is necessary to note that any event at this stage cannot be quality tested, unless a representative segment linked to the bag is present. We have demonstrated that the segment linked to the bag and inside the overwrap correlates well with transplant bag viability, 49 but this needs to be validated individually by each cord blood bank.
The duration of storage for cryopreserved CBU, including assigning an expiration date to CBUs where appropriate, is still not defined. This time should be determined on the basis of the medical literature and/or on the banks' own experimental data. However, if no expiration date has been established, this should be documented by a concurrent/retrospective validation of storage to generate data to use for decision making in the future. The ongoing policy of banks to investigate the effects of long-term storage on CBU includes testing for viability, function and/or stability along time. In future, if this is determined and bags are beyond this time point, the CBU should be discarded.
Distribution and transplantation. Finally, after shipment and before use, there are three potential points wherein product quality can be compromised: (1) in the vapour shipper used for transportation, if the intended temperature The cord blood bank dilemma S Querol et al is not properly achieved; (2) during the transient storage at the transplant centre, because usually there is no appropriate racking to store the canister received; (3) and finally, the thawing method used.
Unfortunately, accidents have been reported at this stage mainly due to excessive transit time or failure in the cryoshipper (the product was received thawed at the transplant centre), or specifically, problems during the handling in the transplant centre especially accidents during thawing (for example, broken cryobags). Table 3 shows the guidelines we use to check suitability of units upon arrival. At that time, if major issues, regarding identity, safety or potency, are detected, the unit needs to be substituted immediately by an alternative one. Therefore, it is recommended that all transplant centres have a back-up CBU reserved that can be immediately shipped. This will avoid significant delay in obtaining new cells for infusion.
The thawing technique remains controversial, despite significant data supporting methods that prevent osmotic shock by DMSO dilution and/or washing. [50] [51] [52] [53] Interestingly, recent data suggest that, especially in adult patients for whom the volume infused can be bigger, an alternative option is dilution (without washing), thereby reducing complexity and validation requirements at transplant centres.
Confirming quality: verification or quality control Certainly, there is controversy regarding how to perform batch quality control; however, a sample from a contiguous segment attached to the transplant bag seems the better method to test the final function of cells present in the product. Special cord blood bag design and adequate releasing tests may become critical to confirm the quality of cord blood products. We comment on a model of cryobag, including small segments that are unmistakably linked to the principal transplant product split into two detachable compartments for cell therapy applications, and developed by the New York Blood Center group. 47 These segments can be used for specific tests with one still remaining, once shipped for quality control at the transplant centre. Such tests may include assays for safety (infectious or genetic disease markers), identity (HLA, ABO, gender) and potency (CFU, viability, functional flow cytometry). [54] [55] [56] [57] However, in our opinion, the responsibility to verify graft potency remains the duty of the cord blood banks (in addition to safety and identity) and not the individual transplant centre. They should expect to purchase a highquality product just as they do for any other clinical product, especially when a poor product may interfere with the outcome of transplantation. Proactive decisions in the cord blood bank discarding non-suitable or undetermined units are expected.
At present, the best test to demonstrate haematopoietic potency is assessing the clonogenic potential. In our particular programmes, we use a parameter that is helpful in identifying problems. That is, the so-called clonogenic efficiency (CLONE), a parameter based on the correlation between CFU and CD34 þ cells (Figure 4) . It means that for a given amount of CD34 þ cells, a defined number of CFUs are expected. We hypothesize that a decrease in the CLONE can predict relevant losses in functionality. As a reference and according our experience, mean clonogenic efficiency (CLONE) corresponding to CB CD34 þ cells is 36±25%. As a safety threshold, we arbitrarily chose 10% or more (equivalent to the mean minus one standard deviation) to qualify a unit as optimal and therefore establishing this correlation as a releasing criterion. This value, if useful, need to be calculated by each cord blood bank and used as an internal reference. This simple The cord blood bank dilemma S Querol et al approach is used in our cord blood banks to discard units that probably lost potency during manufacturing, thereby increasing the likelihood of high-quality effective units. Finally, the most important quality check is the feedback the bank requires from the transplant centre regarding data on cell yields and engraftment. Every deviation would require a thorough analysis of potency data to identify potential problems in manufacturing and prevent the future release of unreliable products. An active communication policy on engraftment outcomes and other quality indicators will help transplant centres in identifying the most reliable cord blood banks. In Table 4 , we propose checklist features that may help transplant centres to identify such establishments.
Proposal for CBU categorization in public inventories
Although HLA matching remains important in CBT, cell dose dependency on outcomes suggests that the cell dose should be used as a major quality criterion. In Figure 5 , we show how the likelihood of finding a donor for a given body weight varies within two cord blood banks having different thresholds of acceptance. To increase the effectiveness of a cord blood inventory, a adequately high threshold need to be establish in order they can benefit as much patients as possible. As shown in Table 5 , units The cord blood bank dilemma S Querol et al transplanted by the Barcelona Cord Blood Programme have progressively increased in size over time. This threshold is especially important in the design of national cord blood inventories. The size of the inventory is calculated on the basis of match categories; however, the units stored should fulfil minimum criteria to make the investment costeffective. In our recently published study, 11 we proposed a minimum of 9 Â 10 8 total nucleated cells as the cost effective threshold.
Finally, to facilitate user decisions around the quality of the cord, we propose to categorize the CBUs into three categories. These categories need to distinguish clearly units with potential issues (category C), from reliable units that can be further classified according to their cellular content as suitable for children (category B) or suitable for adults (category A) (see Table 6 ). Assessment of the inventories based on these categories can give us a real picture of the quality of the current international inventories and the need to replace or discard unreliable units.
Summary
In summary, cord blood banking has developed extensively since the pioneering work by Rubinstein et al. 58 in New York in 1993. Certainly, there has been an impressive increase in activity over the last few years; however, significant quality issues remain. In this paper, we emphasize the need to reinforce validation, in-process quality control and common international accreditation strategies, such as those promoted by FACT-Netcord. Safety and identity issues remain the most critical factors of the cord blood bank responsibility. Extensive manipulation with significant variables such as transit time, storage temperature and cell composition result in unexpected viability problems. In this review, we identify many critical points in the production chain in which the process can damage cells if a proper validation and quality control are not well designed. We support a model of cryobag that allows the verification of not only safety and identity but also potency, and encourages researchers to develop appropriate tests to measure these parameters from the small volume of blood kept in them. Finally, we encourage a revision of the available CBU inventories based on quality categories to help users to identify the most appropriate products. The priority of cord blood banks to improve outcome of CBT should now focus on building quality rather than quantity.
